Clinical Trial Update: A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating RO6927005 alone or with gemcitabine and nab-paclitaxel in mesothelin-positive metastatic or locally advanced malignant solid tumors; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• RO6927005

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Cancer | Phase 1 | Status: TERMINATED